论文部分内容阅读
目的:观察疏血通注射液治疗急性脑梗死的疗效和安全性。方法:110例急性脑梗死患者随机均分为对照组和观察组。对照组患者给予甘露醇、拜阿司匹林、阿托伐他汀、降糖药物等常规治疗;观察组患者在对照组治疗的基础上给予疏血通注射液6ml加入0.9%氯化钠注射液250 ml中,静脉滴注,每日3次。两组患者疗程均为15 d。观察两组患者的临床疗效,治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和特异性烯醇化酶(NSE)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF)-α水平及不良反应发生情况。结果:治疗后,两组患者NIHSS评分和NSE、hs-CRP、TNF-α水平均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上给予疏血通注射液治疗急性脑梗死的疗效和安全性均较好。
Objective: To observe the efficacy and safety of Shuxuetong injection in the treatment of acute cerebral infarction. Methods: One hundred and ten patients with acute cerebral infarction were randomly divided into control group and observation group. Patients in the control group were given routine treatment of mannitol, aspirin, atorvastatin, hypoglycemic drugs, etc .; patients in the observation group were given 6ml of Shuxuetong Injection and 250ml of 0.9% sodium chloride injection on the basis of the treatment of the control group , Intravenous infusion, 3 times a day. Two groups of patients were treated for 15 days. The clinical efficacy of the two groups of patients was observed. NIHSS score, NSE, hs-CRP, TNF- α levels and adverse reactions occurred. Results: After treatment, NIHSS score, NSE, hs-CRP and TNF-α levels in both groups were significantly lower than those before treatment in the two groups and were lower in the observation group than in the control group (P <0.05). The total effective rate in the observation group was significantly higher than that in the control group, the difference was statistically significant (P <0.05). No significant adverse reactions occurred in both groups during treatment. Conclusion: The efficacy and safety of Shuxuetong Injection in the treatment of acute cerebral infarction on the basis of routine treatment are better.